stoxline Quote Chart Rank Option Currency Glossary
  
SCYNEXIS, Inc. (SCYX)
0.776  0.006 (0.79%)    05-23 16:00
Open: 0.7515
High: 0.78
Volume: 87,302
  
Pre. Close: 0.7699
Low: 0.75
Market Cap: 30(M)
Technical analysis
2025-05-23 4:51:00 PM
Short term     
Mid term     
Targets 6-month :  1.12 1-year :  1.28
Resists First :  0.96 Second :  1.1
Pivot price 0.89
Supports First :  0.75 Second :  0.62
MAs MA(5) :  0.78 MA(20) :  0.91
MA(100) :  1.02 MA(250) :  1.38
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  7.1 D(3) :  11
RSI RSI(14): 35.4
52-week High :  2.59 Low :  0.72
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ SCYX ] has closed above bottom band by 15.9%. Bollinger Bands are 16.1% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0.78 - 0.79 0.79 - 0.79
Low: 0.74 - 0.74 0.74 - 0.75
Close: 0.77 - 0.78 0.78 - 0.78
Company Description

SCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States. It offers BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC). The company is developing its lead product candidate, Ibrexafungerp, as a novel oral and intravenous drug for the treatment of various fungal infections, including recurrent VVC, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections; and ibrexafungerp that has completed Phase 3 CANDLE study for the prevention of recurrent (VVC). It has research collaborations with Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC to develop and commercialize rights for ibrexafungerp. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.

Headline News

Sat, 17 May 2025
Here's Why SCYNEXIS (NASDAQ:SCYX) Must Use Its Cash Wisely - simplywall.st

Fri, 16 May 2025
SCYNEXIS Inc reports results for the quarter ended March 31 - Earnings Summary - TradingView

Thu, 15 May 2025
Scynexis: Q1 Earnings Snapshot - MySA

Thu, 15 May 2025
SCYNEXIS Reports First Quarter 2025 Financial Results and Provides Corporate Update | SCYX Stock News - GuruFocus

Thu, 15 May 2025
SCYNEXIS Antifungal Drug Cleared by FDA, but GSK Partnership Hits Major Roadblock - Stock Titan

Tue, 08 Apr 2025
Breakthrough: SCYNEXIS's New Antifungal Drug Defeats 171 Resistant Fungal Strains in Latest Tests - Stock Titan

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Neutral
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Drug Manufacturers - Specialty & Generic
Shares Out 39 (M)
Shares Float 36 (M)
Held by Insiders 2.3 (%)
Held by Institutions 31.1 (%)
Shares Short 691 (K)
Shares Short P.Month 695 (K)
Stock Financials
EPS -0.44
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 1.45
Profit Margin 0 %
Operating Margin -824.3 %
Return on Assets (ttm) -21.2 %
Return on Equity (ttm) -33.3 %
Qtrly Rev. Growth -83.1 %
Gross Profit (p.s.) 0.09
Sales Per Share 0.09
EBITDA (p.s.) -0.94
Qtrly Earnings Growth 0 %
Operating Cash Flow -24 (M)
Levered Free Cash Flow -11 (M)
Stock Valuations
PE Ratio -1.77
PEG Ratio 0
Price to Book value 0.53
Price to Sales 8.07
Price to Cash Flow -1.27
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android